GlycoMimetics, Inc. – NASDAQ:GLYC
GlycoMimetics stock price today
$16.13
+15.89
+6723.18%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in 25 minutes
GlycoMimetics stock price monthly change
-18.11%
month
GlycoMimetics stock price quarterly change
-18.11%
quarter
GlycoMimetics stock price yearly change
-90.52%
year
GlycoMimetics key metrics
Market Cap | 14.18M |
Enterprise value | N/A |
P/E | -1.51 |
EV/Sales | -624.45 |
EV/EBITDA | 1.71 |
Price/Sales | 0.95 |
Price/Book | N/A |
PEG ratio | -0.01 |
EPS | -0.58 |
Revenue | N/A |
EBITDA | -9.84B |
Income | -37.27M |
Revenue Q/Q | N/A |
Revenue Y/Y | -86.67% |
Profit margin | -48544.05% |
Oper. margin | -37376.85% |
Gross margin | 99.9% |
EBIT margin | -37376.85% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGlycoMimetics stock price history
GlycoMimetics stock forecast
GlycoMimetics financial statements
| Jun 2023 | 0 | -8.25M | |
|---|---|---|---|
| Sep 2023 | 0 | -9.20M | |
| Dec 2023 | 10K | -9.07M | -90790% |
| Mar 2024 | 0 | -10.73M |
| Dec 2023 | 10K | -9.07M | -90790% |
|---|---|---|---|
| Mar 2024 | 0 | -10.73M | |
| Oct 2025 | 0 | -12.89M | |
| Dec 2025 | 0 | -22.56M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 61821513 | 7.02M | 11.36% |
|---|---|---|---|
| Sep 2023 | 53201000 | 6.65M | 12.51% |
| Dec 2023 | 45316475 | 6.90M | 15.23% |
| Mar 2024 | 34204913 | 5.29M | 15.48% |
| Jun 2023 | -6.97M | -10.53K | 20.11K |
|---|---|---|---|
| Sep 2023 | -8.68M | -7.86K | 61.61K |
| Dec 2023 | -7.61M | -801 | 999 |
| Mar 2024 | -10.50M | -7.43K | 4.89K |
GlycoMimetics alternative data
| Aug 2023 | 38 |
|---|---|
| Sep 2023 | 38 |
| Oct 2023 | 38 |
| Nov 2023 | 38 |
| Dec 2023 | 38 |
| Jan 2024 | 38 |
| Feb 2024 | 38 |
| Mar 2024 | 38 |
| Apr 2024 | 38 |
| May 2024 | 35 |
| Jun 2024 | 35 |
| Jul 2024 | 35 |
GlycoMimetics other data
50.56%
-2.71%
of GLYC is owned by hedge funds
26.45M
-948.30K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2023 | 65403 | 0 |
| Jun 2024 | 322500 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | ROCK EDWIN officer: Chief Medical Officer | Common Stock | 115,000 | $0.27 | $30,705 | ||
Purchase | ROCK EDWIN officer: Chief Medical Officer | Common Stock | 190,000 | $0.25 | $48,070 | ||
Purchase | HAHN BRIAN M. officer: SVP Fina.. | Common Stock | 17,500 | $0.25 | $4,340 | ||
Purchase | ROCK EDWIN officer: Chief Medical Officer | Common Stock | 30,403 | $1.38 | $41,956 | ||
Purchase | ROCK EDWIN officer: Chief Medical Officer | Common Stock | 35,000 | $1.38 | $48,300 | ||
Option | KOENIG SCOTT director | Common Stock | 21,000 | $0.6 | $12,600 | ||
Option | KOENIG SCOTT director | Stock option (right to buy) | 21,000 | $0.6 | $12,600 | ||
Sale | HAHN BRIAN M. officer: SVP Fina.. | Common Stock | 3,700 | $1.95 | $7,215 | ||
Purchase | JUNIUS DANIEL M director | Common Stock | 30,000 | $1.56 | $46,800 | ||
Purchase | JOHNSON BRUCE S officer: SVP & Chief Commercial.. | Common Stock | 13,500 | $1.57 | $21,195 |
| Patent |
|---|
Grant Utility: Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 Filling date: 7 Aug 2017 Issue date: 6 Sep 2022 |
Application METHODS FOR USE OF GENE EXPRESSION AS AN INDICATOR OF E-SELECTIN INHIBITOR EFFICACY AND CLINICAL OUTCOME FOR MULTIPLE TUMOR TYPES Filling date: 12 Jul 2020 Issue date: 25 Aug 2022 |
Application Filling date: 30 Jul 2020 Issue date: 18 Aug 2022 |
Application Filling date: 21 Apr 2020 Issue date: 14 Jul 2022 |
Application Filling date: 9 Nov 2021 Issue date: 9 Jun 2022 |
Grant Filling date: 17 Aug 2020 Issue date: 17 May 2022 |
Grant Utility: Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin Filling date: 1 Mar 2017 Issue date: 5 Apr 2022 |
Application Filling date: 26 Dec 2019 Issue date: 24 Mar 2022 |
Application Filling date: 26 Dec 2019 Issue date: 10 Mar 2022 |
Grant Filling date: 12 Mar 2018 Issue date: 14 Dec 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 6 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 3 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Brian M. Hahn (1974) Senior Vice President & Chief Financial Officer | $803,520 |
GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real
GlycoMimetics: Q2 2024 Data Readout Makes This Worth A Look, But Cash Is A Problem
GlycoMimetics: Insider Buying Continues, And Chart Looks Healthy
GlycoMimetics: An Asymmetric Opportunity That Could Change Hematology
GlycoMimetics Has Few Risks, Great Outlook In Leukemia
GlycoMimetics: Stock Price Drop Brings Great Speculative Trade Opportunity
GlycoMimetics: A Cancer-Cure Lottery Ticket Grabbing My Attention
GlycoMimetics Could Surge If Q1 Data Readout Is Positive
GlycoMimetics A Buy On Nearing Trial Enrollment Completion
-
What's the price of GlycoMimetics stock today?
One share of GlycoMimetics stock can currently be purchased for approximately $16.13.
-
When is GlycoMimetics's next earnings date?
Unfortunately, GlycoMimetics's (GLYC) next earnings date is currently unknown.
-
Does GlycoMimetics pay dividends?
No, GlycoMimetics does not pay dividends.
-
How much money does GlycoMimetics make?
GlycoMimetics has a market capitalization of 14.18M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 86.65% to 10K US dollars.
-
What is GlycoMimetics's stock symbol?
GlycoMimetics, Inc. is traded on the NASDAQ under the ticker symbol "GLYC".
-
What is GlycoMimetics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of GlycoMimetics?
Shares of GlycoMimetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are GlycoMimetics's key executives?
GlycoMimetics's management team includes the following people:
- Mr. Brian M. Hahn Senior Vice President & Chief Financial Officer(age: 51, pay: $803,520)
-
How many employees does GlycoMimetics have?
As Jul 2024, GlycoMimetics employs 35 workers, which is 8% less then previous quarter.
-
When GlycoMimetics went public?
GlycoMimetics, Inc. is publicly traded company for more then 11 years since IPO on 10 Jan 2014.
-
What is GlycoMimetics's official website?
The official website for GlycoMimetics is glycomimetics.com.
-
Where are GlycoMimetics's headquarters?
GlycoMimetics is headquartered at 9708 Medical Center Drive, Rockville, MD.
-
How can i contact GlycoMimetics?
GlycoMimetics's mailing address is 9708 Medical Center Drive, Rockville, MD and company can be reached via phone at +240 2431201.
GlycoMimetics company profile:
GlycoMimetics, Inc.
glycomimetics.comExchange:
NASDAQ
Full time employees:
35
Industry:
Biotechnology
Sector:
Healthcare
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
9708 Medical Center Drive
Rockville, MD 20850
Rockville, MD 20850
CIK: 0001253689
ISIN: US38000Q1022
CUSIP: 38000Q102
